Consequences of the COVID-19 Lockdown on Health and Well-being of Patients With Parkinson Disease and Post-stroke

Sponsor
University of Haifa (Other)
Overall Status
Completed
CT.gov ID
NCT04535297
Collaborator
(none)
198
1
1.7
118.2

Study Details

Study Description

Brief Summary

The study aimed at describing the effects of the COVID-19 social distancing on function, health and well-being of patients with Parkinson's disease or post-stroke, and test the association between the patient activation level and these effects.An anonymous survey was distributed through social media and patient associations.Community-living patients with Parkinson's disease or post-stroke were invited to answer the survey.

Condition or Disease Intervention/Treatment Phase
  • Other: exposure

Detailed Description

People with chronic diseases like Parkinson's disease or post-stroke rely on routine medical and rehabilitative care to maintain daily function and health. These are important aspects of self-management. However, this was challenged by the social distancing due to COVID-19, which limited participation in regular routines.

The study objectives were: To (1) describe the effects of the COVID-19 social distancing on function, health and well-being of patients with Parkinson's disease or post-stroke, and (2) test the association between the patient activation level and these effects.

Community-living patients with Parkinson's disease or post-stroke were invited to answer an anonymous survey through social media and patient associations. Part 1 included 27 multiple-choice questions regarding current status and changes in function, health, medical care and well-being. Part 2 consisted of the Patient Activation Measure, describing people's knowledge, skill, and confidence in managing their own health.

Study Design

Study Type:
Observational
Actual Enrollment :
198 participants
Observational Model:
Case-Only
Time Perspective:
Cross-Sectional
Official Title:
Consequences of the COVID-19 Lockdown on Health and Well-being of Patients With Parkinson Disease and Post-stroke
Actual Study Start Date :
May 10, 2020
Actual Primary Completion Date :
May 30, 2020
Actual Study Completion Date :
Jun 30, 2020

Outcome Measures

Primary Outcome Measures

  1. Patient Activation Measure (PAMĀ®) [1 hour]

    The PAM is a self-reported validated, licensed tool to measure a patient's knowledge, skills and confidence for self-management. The overall score captures the extent to which people feel engaged and confident in taking care of their health condition. It consists of 13 statements rated on a Likert scale according to agreement. Scores are divided into 4 levels, where 1 represents patients who tend to be passive and feel overwhelmed managing their own health, and 4 represents patients who have effectively adopted self-management behaviors. We used a validated licensed Hebrew and version of the PAM supplied by Insignia Health (https://www.insigniahealth.com/products/pam-survey), which holds the copyright to the questionnaire.

  2. Answers to multiple-choice questions [1 hour]

    participants were asked to answer 27 multiple-choice questions regarding status and change in status of mobility, mood (depression, anxiety), tiredness, social support, body weight, physical activity, rehabilitative treatments and disease symptoms

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • People diagnosed with Parkinson's disease or their caregivers, or people post-stroke or their caregivers

  • Live in the community

  • If a family member or caregiver completed the survey, we asked them to answer in reference to the patient.

Exclusion Criteria:
  • diagnosis of COVID-19

  • hospitalization in the last 3 months.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Galit Yogev-Seligmann Haifa Please Select... Israel 3498838

Sponsors and Collaborators

  • University of Haifa

Investigators

  • Principal Investigator: Galit Yogev-Seligmann, University of Haifa

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Galit Yogev-Seligmann, Dr., University of Haifa
ClinicalTrials.gov Identifier:
NCT04535297
Other Study ID Numbers:
  • 203/20
First Posted:
Sep 1, 2020
Last Update Posted:
Sep 1, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 1, 2020